Top 10 Companies in the United States Pharmaceutical Gelatin Market (2026): Market Leaders Powering Global Pharmaceutical Innovation

The United States pharmaceutical gelatin market stands as a cornerstone of the healthcare sector, underpinning the production of soft and hard capsules, tablet coatings, and advanced drug delivery systems. With a base year of 2025 and a forecast horizon reaching 2034, the market is poised to grow from USD 567.8 million to USD 786.4 million, reflecting a CAGR of 5.6% over the forecast period.

United States Pharmaceutical Gelatin Market – View in Detailed Research Report

Market Insight

Pharmaceutical gelatin is a refined collagen derivative sourced from bovine hides, pig skin, and bones. It undergoes stringent processing to meet pharmaceutical‑grade standards, ensuring safety and efficacy in drug formulations. Its gel‑forming properties make it indispensable as a carrier, protective barrier, and controlled‑release medium in active pharmaceutical ingredient (API) encapsulation.

Market Size

In 2025, the United States market was valued at USD 567.8 million. By 2034, the value is projected to reach USD 786.4 million, driven by escalating demand for gelatin capsules, a shift toward clean‑label products, and automation in manufacturing processes.

Key Drivers

1. Growing demand for soft and hard capsules as patient‑friendly dosage forms.
2. Strict compliance with USP and EP quality specifications, reinforcing safety and reliability.
3. Automation and process innovations boosting yields by up to 40%, enhancing scalability.
4. Consumer momentum toward clean‑label, organic, and non‑GMO products, accelerating market expansion.

Restraints

1. Ethical and religious concerns surrounding animal‑derived gelatin limit market penetration in certain segments.
2. Volatility in raw material prices (pig skin, bovine hides, bones) can compress margins.

Opportunities

1. Vegetarian and halal alternatives, projected to capture 15% of market share, meet dietary restrictions.
2. Controlled‑release technology enhances therapeutic efficacy and patient adherence.
3. Rising investment in pharmaceutical R&D positions gelatin as a key component in next‑generation drug delivery.

Challenges

1. Synthetic capsule materials such as HPMC pose competitive pressure, offering vegetarian certification.
2. Environmental sustainability concerns around animal‑sourced raw materials drive demand for greener practices.

Top 10 Companies in the United States Pharmaceutical Gelatin Market (2026)

1️⃣ Rousselot

Headquarters: Paris, France
Key Offering: Pharmaceutical‑grade gelatin for capsules, tablets, and advanced drug delivery.

Rousselot leverages a global supply chain and state‑of‑the‑art purification processes to deliver consistent quality. The company has recently expanded its plant in the Midwest, boosting capacity by 20%.

Sustainability Initiatives:

• Closed‑loop waste management reducing by 30%.
• Investment in renewable energy for production facilities.
• Partnerships with animal welfare NGOs to ensure ethical sourcing.

2️⃣ Gelita AG

Headquarters: Duisburg, Germany
Key Offering: Broad portfolio of pharmaceutical gelatin, including vegetarian and halal‑certified variants.

Gelita’s commitment to sustainability is reflected in its carbon‑neutral manufacturing footprint and use of recycled water.

Sustainability Initiatives:

• Carbon neutrality target by 2030.
• Biodegradable packaging for gelatin products.
• Transparency in supply chain traceability.

3️⃣ Catalent Pharma Solutions

Headquarters: Wilmington, Delaware, USA
Key Offering: Advanced drug delivery technologies incorporating pharmaceutical gelatin.

With a focus on precision dosage, Catalent integrates gelatin into controlled‑release platforms for oncology and chronic disease therapies.

Innovation Highlights:

• Customizable release profiles via gelatin matrix engineering.
• Collaboration with biotech firms for personalized medicine.
• Digital monitoring of capsule integrity.

4️⃣ Pfizer Inc.

Headquarters: New York, USA
Key Offering: Pharmaceutical gelatin for vaccine and therapeutic capsule production.

Pfizer’s extensive R&D pipeline ensures gelatin is tailored for high‑efficacy formulations, including mRNA vaccine encapsulation.

Strategic Moves:

• Investment in biomanufacturing facilities across the Midwest.
• Partnerships with global health agencies.
• Focus on scalable, GMP‑compliant gelatin production.

5️⃣ Merck & Co., Inc.

Headquarters: Kenilworth, New Jersey, USA
Key Offering: Gelatin‑based capsules for chronic disease management.

Merck’s product development aligns with patient‑centric dosing, emphasizing ease of swallowing and bioavailability.

Patient‑Focused Initiatives:

• Patient adherence studies linked to gelatin capsule design.
• Collaboration with patient advocacy groups.
• Development of child‑friendly gelatin formulations.

6️⃣ GSK (GlaxoSmithKline)

Headquarters: London, UK
Key Offering: Pharmaceutical gelatin for vaccines and oral therapies.

GSK integrates gelatin into its vaccine delivery platform, ensuring stability and shelf‑life.

Innovation Highlights:

• Gelatin‑based adjuvant formulations.
• Digital supply chain for raw material traceability.
• Investments in sustainable sourcing.

7️⃣ Johnson & Johnson

Headquarters: New Brunswick, New Jersey, USA
Key Offering: Gelatin for medical device coatings and drug delivery systems.

Johnson & Johnson’s multidisciplinary approach blends gelatin with polymer coatings for enhanced drug release.

Strategic Focus:

• Integration of gelatin in implantable devices.
• Collaborations with research institutions.
• Commitment to ethical sourcing.

8️⃣ Eli Lilly and Company

Headquarters: Indianapolis, Indiana, USA
Key Offering: Gelatin‑based capsules for diabetes and oncology therapeutics.

Lilly’s gelatin formulations prioritize patient adherence and controlled release.

Key Initiatives:

• Clinical trials on gelatin‑encapsulated drug delivery.
• Partnerships with patient advocacy groups.
• Investment in sustainable manufacturing.

9️⃣ AbbVie Inc.

Headquarters: North Chicago, Illinois, USA
Key Offering: Pharmaceutical gelatin for immunology and dermatology products.

AbbVie focuses on gelatin’s role in delivering biologics and small molecules with high bioavailability.

Innovation Highlights:

• Gelatin‑based delivery for biologic therapies.
• Collaborations with biotech startups.
• Digital tracking of gelatin batch quality.

🔟 Teva Pharmaceuticals

Headquarters: Petah Tikva, Israel
Key Offering: Generic pharmaceutical gelatin for capsules and tablets.

Teva’s extensive portfolio leverages gelatin to produce cost‑effective generics with consistent quality.

Strategic Focus:

• Expansion of manufacturing in the U.S. Midwest.
• Collaboration with global health organizations.
• Investment in renewable energy for production.

Download FREE Sample Report

United States Pharmaceutical Gelatin Market – View in Detailed Research Report

Get Full Report

United States Pharmaceutical Gelatin Market – View in Detailed Research Report

Outlook

The United States market is expected to maintain a steady upward trajectory, supported by robust demand from pharmaceutical manufacturing hubs in the Northeast, Midwest, and South. Technological advancements in automation and precision dosing are anticipated to drive efficiency gains and product differentiation.

Future Trends

• Expansion of vegetarian and halal gelatin offerings to capture niche consumer segments.
• Integration of controlled‑release platforms to improve therapeutic outcomes.
• Adoption of digital twins for gelatin production to optimize process parameters.
• Increasing collaboration between pharmaceutical companies and gelatin suppliers to co‑develop next‑generation drug delivery systems.
• Focus on circular economy practices, including waste reduction and renewable energy utilization.